American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

ImmunityBio, Inc. (IBRX)

$7.81 -4.99% NASDAQ: IBRX · 15-min delayed

SAN DIEGO, California
Public · NASDAQ: IBRX
691 employees

Visit website Follow

$7.4BMarket cap

$113.3MRevenue · FY2025

-$351.4MNet income

691Employees

IBRXNASDAQ

2021IPO

About ImmunityBio, Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: IBRX
Employees: 691
IPO date: Mar 10, 2021
Headquarters: 3530 JOHN HOPKINS COURT
SAN DIEGO, California 92121
Phone: (844) 696-5235
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: DE, United States
Registered office: Dover, US
Legal entity ID: 529900J9XLBR4HFL4B83

Source: GLEIF, the global Legal Entity Identifier registry · checked Jul 26, 2026. A US headquarters does not always mean US incorporation.

Registry IDs

Ticker: IBRX Nasdaq
SEC CIK: 1326110
LEI: 529900J9XLBR4HFL4B83
EIN: 431979754
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show ImmunityBio, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/immunitybio-inc/"><img src="https://americancompanies.com/badge/immunitybio-inc.svg" alt="ImmunityBio, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow ImmunityBio, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $113.3M
Net income: -$351.4M
Total assets: $501.9M
Market cap: $7.4B

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: IBRX

$7.81 -4.99%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$1.98 $11.55

52-week range

Market cap: $7.4B
Shares outstanding: 952.1M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Mar 10, 2021

ImmunityBio, Inc. (IBRX) Stock Price

Reported a net loss of $351.4M in FY2025.
Trading 32% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review ImmunityBio, Inc..

Write a review

Newsroom

News about ImmunityBio, Inc.

FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer Zacks Investment Research · 2026-10-15 · positive INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX GlobeNewswire Inc. · 2026-05-26 · negative IBRX DEADLINE TOMORROW: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX GlobeNewswire Inc. · 2026-05-25 · negative IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm GlobeNewswire Inc. · 2026-05-25 · negative IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX GlobeNewswire Inc. · 2026-05-22 · negative IBRX 4-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims – Hagens Berman GlobeNewswire Inc. · 2026-05-22 · negative

News & sentiment via Polygon.io

FAQ

ImmunityBio, Inc.: frequently asked questions

Is ImmunityBio, Inc. an American company?

ImmunityBio, Inc. is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is ImmunityBio, Inc. headquartered?

ImmunityBio, Inc. is headquartered in San Diego, California, United States.

Is ImmunityBio, Inc. publicly traded?

Yes — ImmunityBio, Inc. is a publicly traded company. Its stock trades under the ticker symbol IBRX on the NASDAQ.

What does ImmunityBio, Inc. do?

ImmunityBio, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore